Leerink Maintains Outperform on BBIO, BridgeBio Pharma, Inc. March 12, 2026
Leerink Partners maintained an Outperform on BridgeBio Pharma, Inc. (BBIO) on March 12, 2026, marking a clear BBIO analyst rating ahead of further clinical readouts. The note accompanied a company data presentation and described the risk/reward skewed to the upside. Leerink did not publish a new price target in this note. This reiteration signals continued confidence from a specialist biotech desk and keeps BBIO in analysts’ buy-conviction sets.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
